person · Reporting owner
D'Ambrosio Donald Eric
Disclosed activity across 2 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Emmaus Life Sciences, Inc.MYND · Entity 205 | Chief Financial Officer | June 25, 2019 | June 26, 2019 |
| Telemynd, Inc.NONE · Entity 155932 | Chief Financial Officer | July 16, 2019 | July 18, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Emmaus Life Sciences, Inc.
Report date June 25, 2019 · Filed June 26, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| EMPLOYEE STOCK OPTION (right to purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $1.18 · Expires 2029-06-25 | Direct | 10,000 |
Reported balance
After 2019-06-25 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-06-25 · Grant · Acquired 10,000 · Balance 10,000 F1: On June 25, 2019, the Reporting Person was granted an option to purchase 10,000 shares of common stock under the MYnd Analytics, Inc. Amended and Restated 2012 Omnibus Incentive Compensation Plan. All of the options vested on the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: On June 25, 2019, the Reporting Person was granted an option to purchase 10,000 shares of common stock under the MYnd Analytics, Inc. Amended and Restated 2012 Omnibus Incentive Compensation Plan. All of the options vested on the grant date.
Telemynd, Inc.
Report date July 16, 2019 · Filed July 18, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 7,500 |
Reported balance
After 2019-07-16 transaction · row 1
1 source rowRow 1 · 2019-07-16 · Other · Acquired 7,500 · Balance 7,500 F1: Telemynd, Inc. ("Telemynd") was formerly a wholly-owned subsidiary of MYnd Analytics, Inc. ("MYnd"). On July 15, 2019, pursuant to the Amended and Restated Separation and Distribution Agreement, dated as of March 27, 2019, between MYnd and Telemynd, the Reporting Person received a pro rata distribution of common stock of Telemynd. |
Filing footnotes · ownership attribution and instrument terms
F1: Telemynd, Inc. ("Telemynd") was formerly a wholly-owned subsidiary of MYnd Analytics, Inc. ("MYnd"). On July 15, 2019, pursuant to the Amended and Restated Separation and Distribution Agreement, dated as of March 27, 2019, between MYnd and Telemynd, the Reporting Person received a pro rata distribution of common stock of Telemynd.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 16, 2019 Filed Jul 18, 2019 18:44 UTC | Telemynd, Inc. NONE · Entity 155932 | OtherCommon Stock | 7,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-19-013139 · ownership.xml · nonDerivative · entry 1 D'Ambrosio Donald Eric · CIK 0001701944 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 F1 · shares: Telemynd, Inc. ("Telemynd") was formerly a wholly-owned subsidiary of MYnd Analytics, Inc. ("MYnd"). On July 15, 2019, pursuant to the Amended and Restated Separation and Distribution Agreement, dated as of March 27, 2019, between MYnd and Telemynd, the Reporting Person received a pro rata distribution of common stock of Telemynd. F1 · price: Telemynd, Inc. ("Telemynd") was formerly a wholly-owned subsidiary of MYnd Analytics, Inc. ("MYnd"). On July 15, 2019, pursuant to the Amended and Restated Separation and Distribution Agreement, dated as of March 27, 2019, between MYnd and Telemynd, the Reporting Person received a pro rata distribution of common stock of Telemynd. Read SEC document |
| June 25, 2019 Filed Jun 26, 2019 23:26 UTC | Emmaus Life Sciences, Inc. MYND · Entity 205 | GrantEMPLOYEE STOCK OPTION (right to purchase) · Derivative | 10,000 | $0.00 Strike: $1.18 | $0.00 |
DisclosureSEC source: 0001213900-19-011554 · ownership.xml · derivative · entry 1 D'Ambrosio Donald Eric · CIK 0001701944 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2029-06-25 F1 · shares: On June 25, 2019, the Reporting Person was granted an option to purchase 10,000 shares of common stock under the MYnd Analytics, Inc. Amended and Restated 2012 Omnibus Incentive Compensation Plan. All of the options vested on the grant date. F1 · derivative.expiration_date: On June 25, 2019, the Reporting Person was granted an option to purchase 10,000 shares of common stock under the MYnd Analytics, Inc. Amended and Restated 2012 Omnibus Incentive Compensation Plan. All of the options vested on the grant date. Read SEC document |
| December 03, 2018 Filed Dec 6, 2018 22:31 UTC | Emmaus Life Sciences, Inc. MYND · Entity 205 | GrantEMPLOYEE STOCK OPTION (right to purchase) · Derivative | 26,500 | $0.00 Strike: $1.46 | $0.00 |
DisclosureSEC source: 0001615774-18-013954 · s114542_form4.xml · derivative · entry 1 D'Ambrosio Donald Eric · CIK 0001701944 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,500 Underlying: Common Stock · 26,500 shares Expires 2028-12-03 F1 · shares: On December 03, 2018, the Reporting Person was granted an option to purchase 26,500 shares of common stock under the MYnd Analytics, Inc. Amended and Restated 2012 Omnibus Incentive Compensation Plan. 8,834 of the options vested on the grant date (December 3, 2018), with 8,833 vesting on the first anniversary of the grant date and 8,833 vesting on the second anniversary of the grant date. F1 · derivative.expiration_date: On December 03, 2018, the Reporting Person was granted an option to purchase 26,500 shares of common stock under the MYnd Analytics, Inc. Amended and Restated 2012 Omnibus Incentive Compensation Plan. 8,834 of the options vested on the grant date (December 3, 2018), with 8,833 vesting on the first anniversary of the grant date and 8,833 vesting on the second anniversary of the grant date. F1 · balance_after: On December 03, 2018, the Reporting Person was granted an option to purchase 26,500 shares of common stock under the MYnd Analytics, Inc. Amended and Restated 2012 Omnibus Incentive Compensation Plan. 8,834 of the options vested on the grant date (December 3, 2018), with 8,833 vesting on the first anniversary of the grant date and 8,833 vesting on the second anniversary of the grant date. Read SEC document |
| October 08, 2018 Filed Oct 11, 2018 00:08 UTC | Emmaus Life Sciences, Inc. MYND · Entity 205 | GrantEMPLOYEE STOCK OPTION (right to purchase) · Derivative | 30,000 | $0.00 Strike: $1.38 | $0.00 |
DisclosureSEC source: 0001615774-18-010695 · s113233_form4.xml · derivative · entry 1 D'Ambrosio Donald Eric · CIK 0001701944 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2028-10-08 F1 · shares: On October 8, 2018, the Reporting Person was granted an option to purchase 30000 shares of common stock under the MYnd Analytics, Inc. Amended and Restated 2012 Omnibus Incentive Compensation Plan, subject to shareholder approval of an amendment increasing the total shares available for grant thereunder. 5000 of the options vested on the grant date, with the remainder vesting upon the satisfaction of specified performance targets. F1 · derivative.expiration_date: On October 8, 2018, the Reporting Person was granted an option to purchase 30000 shares of common stock under the MYnd Analytics, Inc. Amended and Restated 2012 Omnibus Incentive Compensation Plan, subject to shareholder approval of an amendment increasing the total shares available for grant thereunder. 5000 of the options vested on the grant date, with the remainder vesting upon the satisfaction of specified performance targets. F1 · balance_after: On October 8, 2018, the Reporting Person was granted an option to purchase 30000 shares of common stock under the MYnd Analytics, Inc. Amended and Restated 2012 Omnibus Incentive Compensation Plan, subject to shareholder approval of an amendment increasing the total shares available for grant thereunder. 5000 of the options vested on the grant date, with the remainder vesting upon the satisfaction of specified performance targets. Read SEC document |
| April 04, 2018 Filed Apr 26, 2018 21:19 UTC | Emmaus Life Sciences, Inc. MYND · Entity 205 | GrantEmployee Stock Option (right to purchase) · Derivative | 18,000 | $0.00 Strike: $1.55 | $0.00 |
DisclosureSEC source: 0001615774-18-002939 · s109818_form4.xml · derivative · entry 1 D'Ambrosio Donald Eric · CIK 0001701944 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,000 Underlying: Common Stock · 18,000 shares Expires 2028-04-04 F1 · shares: On April 4, 2018, the reporting person was granted an option to purchase 18,000 shares of common stock. The option vests in four equal installments based on the reporting person's satisfaction of certain performance criteria. Three of the four milestones have been satisfied. F1 · balance_after: On April 4, 2018, the reporting person was granted an option to purchase 18,000 shares of common stock. The option vests in four equal installments based on the reporting person's satisfaction of certain performance criteria. Three of the four milestones have been satisfied. Read SEC document |
| November 13, 2017 Filed Nov 20, 2017 22:50 UTC | Emmaus Life Sciences, Inc. MYND · Entity 205 | GrantCommon Stock | 7,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001615774-17-006923 · s108240_form4.xml · nonDerivative · entry 1 D'Ambrosio Donald Eric · CIK 0001701944 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 F1 · shares: Granted pursuant to compensatory arrangements. Read SEC document |
| September 18, 2017 Filed May 11, 2018 21:02 UTC Amendment | Emmaus Life Sciences, Inc. MYND · Entity 205 | GrantEmployee Stock Option (right to purchase) · Derivative | 18,000 | $0.00 Strike: $3.53 | $0.00 |
DisclosureSEC source: 0001615774-18-003639 · s110117_form4a.xml · derivative · entry 1 D'Ambrosio Donald Eric · CIK 0001701944 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,000 Underlying: Common Stock · 18,000 shares Expires 2027-09-18 F1 · shares: On September 18,2017, the reporting person was granted an option to purchase 18,000 shares of common stock. The grant of these options was contingent upon shareholder approval of an amendment to MYnd Analytics, Inc. Amended and Restated 2012 Omnibus Incentive Compensation Plan (the "Plan") at the Company's 2018 Annual Meeting of Shareholders, increasing the total number of shares available for grant and an increase to the evergreen provision of the Plan. Such shareholder approval was obtained at the Company's 2018 Annual Meeting of Shareholders on April 4, 2018.The option vests in four equal installments based on the reporting person's satisfaction of certain performance criteria. The performance criteria for three of the four installments have been met, resulting in the vesting of an option to purchase 13,500 shares of common stock, as of the date of this filing. F1 · balance_after: On September 18,2017, the reporting person was granted an option to purchase 18,000 shares of common stock. The grant of these options was contingent upon shareholder approval of an amendment to MYnd Analytics, Inc. Amended and Restated 2012 Omnibus Incentive Compensation Plan (the "Plan") at the Company's 2018 Annual Meeting of Shareholders, increasing the total number of shares available for grant and an increase to the evergreen provision of the Plan. Such shareholder approval was obtained at the Company's 2018 Annual Meeting of Shareholders on April 4, 2018.The option vests in four equal installments based on the reporting person's satisfaction of certain performance criteria. The performance criteria for three of the four installments have been met, resulting in the vesting of an option to purchase 13,500 shares of common stock, as of the date of this filing. Read SEC document |
| July 14, 2017 Filed Jul 19, 2017 00:55 UTC | Emmaus Life Sciences, Inc. MYND · Entity 205 | GrantEmployee Stock Option (right to purchase) · Derivative | 3,000 | $0.00 Strike: $5.90 | $0.00 |
DisclosureSEC source: 0001615774-17-003709 · s106848_form4.xml · derivative · entry 1 D'Ambrosio Donald Eric · CIK 0001701944 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,000 Underlying: Common Stock · 3,000 shares Expires 2027-03-31 F1 · balance_after: In March 2017, the reporting person was granted an option to purchase 18,000 shares of common stock (the "Option Grant"). As previously reported, the Option Grant vests as to 15,000 shares in 36 equal monthly installments from March 31, 2017. Vesting of the Option Grant as to the remaining 3,000 shares was subject to satisfaction by the issuer of a performance condition. The performance condition was met on July 14, 2017, resulting in vesting of the Option Grant as to the remaining 3,000 shares. Read SEC document |
| March 31, 2017 Filed Apr 5, 2017 00:09 UTC | Emmaus Life Sciences, Inc. MYAN · Entity 205 | GrantEmployee Stock Option (right to purchase) · Derivative | 15,000 | $0.00 Strike: $5.90 | $0.00 |
DisclosureSEC source: 0001615774-17-001494 · s105793_form4.xml · derivative · entry 1 D'Ambrosio Donald Eric · CIK 0001701944 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2027-03-31 F1 · derivative.exercise_date: The option vests in 36 equal monthly installments from March 31, 2017. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.